BiogenIdec, Elan Up on Drug Data Shares in BiogenIdec (BIIB:Nasdaq - news - research) and Elan (ELN:NYSE - news - research)rose early Monday after the companies released what they described as  quot;compelling quot; phase III test results for their multiple sclerosis drug Antegren.